← Leaderboards
Mizuki Nishino
Brigham And Women'S Hospital
$3,762,703
Attributed
$3,762,703
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $606.6K · FY2011–21$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$3,762,703 · 2
By mechanism
R01$2,860,903 · 1
K23$901,800 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Mario Luca Suva$9,318,589
- David W Sternberg$557,280
- Connie Meeyoung Rhee$6,865,715
- Carolyn Y Ho$13,169,103
- Stephen J Elledge$15,349,506
Others in their field
Top investigators on “Non-Small-Cell Lung Carcinoma”
- Walter John Curran · Thomas Jefferson University$26,641,549
- Pasi A Janne · Stanford University$23,565,845
- Kwok Kin Wong · New York University School Of Medicine$17,033,021
- Trever G Bivona · University Of California, San Francisco$12,986,639
- Reuben J Shaw · Salk Institute For Biological Studies$11,952,012
- Matthew L Meyerson · Brigham And Women'S Hospital$11,175,304
Research focus
Non-Small-Cell Lung CarcinomaWomanImageMutationResponseTumor VolumeEpidermal Growth Factor ReceptorEvaluationMalignant Neoplasm Of LungMeasurementOncologistProspectiveTumorCancer PatientCancer TherapyComputer SoftwareEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorClinical ApplicationBaseInhibitor/AntagonistMalignant NeoplasmsClinical TrialsCohortX-Ray Computed Tomography
Grant awards (10)
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment$567,838
R01 · FY2021 · CA · contact PI
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment$567,838
R01 · FY2020 · CA · contact PI
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment$550,802
R01 · FY2019 · CA · contact PI
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment$567,838
R01 · FY2018 · CA · contact PI
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment$606,587
R01 · FY2017 · CA · contact PI
CT Volume Measurement of Lung Cancer treated with Erlotinib: Genomic Correlation$180,360
K23 · FY2015 · CA · contact PI
CT Volume Measurement of Lung Cancer treated with Erlotinib: Genomic Correlation$180,360
K23 · FY2014 · CA · contact PI
CT Volume Measurement of Lung Cancer treated with Erlotinib: Genomic Correlation$180,360
K23 · FY2013 · CA · contact PI
CT Volume Measurement of Lung Cancer treated with Erlotinib: Genomic Correlation$180,360
K23 · FY2012 · CA · contact PI
CT Volume Measurement of Lung Cancer treated with Erlotinib: Genomic Correlation$180,360
K23 · FY2011 · CA · contact PI